- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04605705
NIRS for the Diagnosis and Prevention of Acute Renal Failure
NIRS: a Tool for the Diagnosis and Prevention of Acute Renal Failure in Pediatric Cardiac Surgery
This prospective study will take place at Hotel Dieu de France hospital in Lebanon. One hundred children undergoing cardiac surgery for congenital heart disease between May 2020 and May 2021 will be included. After obtaining the informed consent of the parents, demographic and surgical information will be collected. Serum creatinine, lactic acid, urinary neutrophil gelatinase-associated lipocalin marker (NGAL), and oxygen (O2) saturation will be measured before the operation.
A pediatric NIRS sensor will be placed on the right side below the costo-vertebral angle overlying the right kidney and continuous regional oxygen saturation (rSO2) will be recorded every 5 to 10 minutes throughout the operation until 24 hours after surgery. The children will be divided into 2 groups; 50 each. Grp 1: No clinical intervention was performed based on NIRS values. Grp 2: several maneuvers are performed such as an increase in cardiac output, temperature, hemoglobin to optimize the value of NIRS > 80%. All patients will receive standard standard care during the study period and continuous infusion of furosemide (0.5-1 mg / kg / 6 hours) within the first 24-48 hours postoperatively will be administered to all patients. Creatinine and lactic acid will be measured immediately postoperatively and then once a day until D2 and D7.
The urinary NGAL marker will be dosed immediately postoperatively and then at 2h, 6h, 12h and 24h with hourly monitoring of diuresis and NIRS until 24h postoperatively.
Study Overview
Status
Conditions
Detailed Description
This prospective study will take place at Hotel Dieu de France hospital in Lebanon. One hundred children aged 16 and under, undergoing cardiac surgery with cardiopulmonary bypass (CPB) for congenital heart diseases will be included between May 2020 and May 2021. The surgeries to be included will be the tetralogy of Fallot, transposition of the great arteries, ventricular septal defect, atrial septal defect and the atrioventricular canal defect. Any premature under 35 weeks of gestation, the presence of a genetic disease, an abnormal renal ultrasound, a preoperative renal failure with creatinine abnormal for age, or repeated urinary tract infections will be excluded from the study. After obtaining the informed consent of the parents, demographic information (age, weight, height, sex) will be collected..
Serum creatinine, lactic acid, urinary NGAL marker, and O2 saturation will be measured before the operation.
A pediatric NIRS sensor will be placed on the right side below the costo-vertebral angle covering the right kidney and continuous rSO2 will be recorded every 5 to 10 minutes throughout the operation as well as with each change of situation, then every hour in pediatric resuscitation until 24 hours postoperatively. The children will be divided into 2 groups of 50 patients each; Grp 1: No clinical intervention will be performed based on the NIRS and Grp 2: several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
Surgical information (cardiac pathology, surgical procedure, operating time, duration of CPB, duration of aortic cross-clamping, duration of circulatory arrest, intraoperative complications) will be collected.
All patients will receive standard standard care during the study period. Patients will receive continuous infusion of furosemide (0.5-1 mg / kg / 6 hours) within the first 24-48 hours postoperatively.
Postoperatively, the need for catecholamines, the hemodynamic stability according to the Vasoactive-Inotropic Score (VIS), the delay to extubation, the stay in intensive care, the complications that occurred and the need for recourse to the dialysis will be noted.
Creatinine and lactic acid will be measured immediately postoperatively and then once a day until D2 and D7.
The urinary NGAL marker will be dosed immediately postoperatively and then at 2h, 6h, 12h and 24h with hourly monitoring of diuresis and NIRS until 24h postoperatively.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Beirut, Lebanon, 166830
- Recruiting
- Hotel Dieu de France Hospital
-
Contact:
- AFRIDA H GERGESS, M.D.
- Phone Number: 009613957831
- Email: gergessafrida@gmail.com
-
Sub-Investigator:
- khalil Jabbour, M.D.
-
Sub-Investigator:
- Samia Madi-Jebara, M.D.
-
Sub-Investigator:
- Elie B Sawan, M.D.
-
Sub-Investigator:
- Cynthia Najarian, M.D.
-
Sub-Investigator:
- Gemma Hayek, M.D.
-
Principal Investigator:
- Afrida H Gergess, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pediatric patients aged 16 years and under, undergoing cardiac surgery with cardiopulmonary bypass at the hotel Dieu de France Hospital, from September 2020 until September 2021.
- Surgeries to include: Tetralogy of Fallot, Transposition of great Vessels, ventricular septal defect, atrial septal defect and atrioventricular septal defect.
- Normal renal function
- Informed consent written and signed by the child's parents
Exclusion Criteria:
- The refusal of the patient's parents
- Patients with preoperative AKI
- Identification of renal or urinary anatomical abnormalities
- Premature infants <35 weeks of gestation
- Children with a known genetic or chromosomal abnormality
- Destination to a uni ventricular repair
- Repeated urinary tract infections before the surgery
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Group 1
NIRS values will be recorded during the surgery and until 24 hours postoperatively.
No intervention will be done.
|
|
|
Group 2
Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
|
Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Impact of low renal NIRS values on renal function in children undergoing cardiac surgery.
Time Frame: 7 days
|
Monitoring renal NIRS values during the surgery and until 24 hours in the ICU.
All values are recorded.
A dosage of creatinine is made upon arrival to the ICU , 24 hours later and one week later.
A correlation between NIRS values and creatinine changes will be noticed.
|
7 days
|
|
Improving NIRS values prevent acute kidney injury in children undergoing cardiac surgery.
Time Frame: 7 days
|
Optimizing renal NIRS values in children undergoing cardiac surgery.
Each drop in NIRS values below 10% of its baseline is treated with transfusion and increasing the flow of CPB.
Postoperatively, creatinine dosage is made upon arrival to the ICU, At day 1 and 7.
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Need for dialysis
Time Frame: 7 days
|
Need for dialysis during the 1st week after the surgery
|
7 days
|
|
Duration of mechanical ventilation
Time Frame: 7 days
|
Length of intubation and mechanical ventilation within the 1st postoperative week
|
7 days
|
|
Length of stay in intensive care units (ICU)
Time Frame: 1 month
|
The length of stay in ICU within the 1st month after the surgery
|
1 month
|
|
Deaths within 30 days postoperative
Time Frame: 30 days
|
Deaths within 30 days in children after cardiac surgery
|
30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: AFRIDA GERGESS, M.D., Hotel Dieu de France Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FM389
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Insufficiency, Acute
-
Centre Hospitalier Universitaire DijonCompletedPatients With Acute Renal InsufficiencyFrance
-
University Hospital, GrenobleRecruitingRenal Insufficiency | Renal Failure | Acute Renal Failure | Acute Renal InsufficiencyFrance
-
Vanessa Stadlbauer-Koellner, MDAustrian Science Fund (FWF)CompletedAcute Renal Failure | Chronic Renal InsufficiencyAustria
-
Icahn School of Medicine at Mount SinaiJohns Hopkins University; Mayo Clinic; National Institute of Diabetes and Digestive... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
PfizerCompletedRenal Insufficiency, Chronic | Renal Insufficiency, Acute | Renal Disease, End-StageUnited States
-
Ziekenhuis Netwerk Antwerpen (ZNA)TerminatedRenal Replacement Therapy | Renal Insufficiency, AcuteBelgium
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsCompletedCovid19 | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Sars-CoV-2 Infection | Acute Kidney Insufficiency | Renal Failure, Acute | Kidney Insufficiency, AcuteUnited States
-
Medizinisches Versorgungszentrum Diaverum PotsdamUniversity of Magdeburg; Ernst von Bergmann HospitalRecruitingAcute Renal InsufficiencyGermany
-
Rempex (a wholly owned subsidiary of Melinta Therapeutics...Innovative Medicines Initiative; Universitätsklinikum KölnTerminatedRenal Insufficiency, Chronic | Healthy Subjects | Renal Insufficiency, AcuteGermany
-
Central Hospital, Nancy, FranceCompletedRenal Insufficiency, AcuteFrance
Clinical Trials on Optimization of the cardiac output, the temperature, the hemoglobin in order to have the NIRS value by up to 80%.
-
Cambridge University Hospitals NHS Foundation TrustObstetric Anaesthetists' AssociationRecruitingAnesthesiaUnited Kingdom
-
University of MilanLuigi Sacco University HospitalCompletedCOVID19 | BETA-CELL FUNCTIONItaly
-
Aalborg University HospitalUniversity of AarhusCompletedPulmonary EmbolismDenmark
-
University of British ColumbiaNovo Nordisk A/STerminatedType 2 Diabetes | Peripheral Vascular DiseaseCanada
-
Memorial Sloan Kettering Cancer CenterPfizer; Dana-Farber Cancer Institute; University of Pittsburgh; University of VirginiaCompletedNeurofibromatosis | Meningioma | CNS Cancer | Hemangioblastoma | Intracranial HemangiopericytomaUnited States
-
Wake Forest University Health SciencesRecruitingTibial Fractures | Open tíbia Fracture | Osteomyelitis TibiaUnited States
-
Northwestern UniversityAmerican College of Surgeons; Accreditation Council for Graduate Medical Education and other collaboratorsCompletedPatient Safety | Resident Work Hours
-
Memorial Sloan Kettering Cancer CenterTufts Medical Center; Lahey ClinicCompleted